Efficacy of gefitinib‑celecoxib combination therapy in docetaxel‑resistant prostate cancer-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Efficacy of gefitinib‑celecoxib combination therapy in docetaxel‑resistant prostate cancer

Published:2018-07-24 Issue: Volume: Page:
ISSN:1021-335X
Container-title:Oncology Reports
language:
Short-container-title:Oncol Rep

Author:

Lin Jian‑Zhong¹,Hameed Irbaz²,Xu Zhen³,Yu Yang⁴,Ren Zhi‑Yun⁵,Zhu Jia‑Geng⁶

Affiliation:

1. Department of Urology and Central Laboratory, BenQ Medical Center, Nanjing Medical University, Nanjing, Jiangsu�210019, P.R.�China

2. Department of Cancer Research, Southeast University, Nanjing, Jiangsu�210009, P.R. China

3. Department of Urology, Taizhou People's Hospital, Taizhou, Jiangsu�225300, P.R. China

4. Department of Cancer Research, The First Clinical Medical College, Nanjing Medical University, Nanjing, Jiangsu�211166, P.R. China

5. Central Laboratory, BenQ Medical Center, Nanjing Medical University, Nanjing, Jiangsu�210019, P.R. China

6. Department of Urology, Nanjing First Hospital, Nanjing Medical University, Nanjing, Jiangsu�210006, P.R.�China

Publisher

Spandidos Publications

Subject

Cancer Research,Oncology,General Medicine

Cited by 10 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Integration of Pan-Cancer Cell Line and Single-Cell Transcriptomic Profiles Enables Inference of Therapeutic Vulnerabilities in Heterogeneous Tumors;Cancer Research;2024-04-06

2. COX 2-inhibitors; a thorough and updated survey into combinational therapies in cancers;Medical Oncology;2024-01-02

3. The Potential Preventive and Therapeutic Roles of NSAIDs in Prostate Cancer;Cancers;2023-11-16

4. Gefitinib: An Updated Review of its Role in the Cancer Management, its Nanotechnological Interventions, Recent Patents and Clinical Trials;Recent Patents on Anti-Cancer Drug Discovery;2023-11

5. Inferring therapeutic vulnerability within tumors through integration of pan-cancer cell line and single-cell transcriptomic profiles;2023-11-01

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3